Substrate specificity of plasma lecithin: cholesterol acyltransferase in abetalipoproteinemia.
The lecithin: cholesterol acyltransferase (LCAT) activity of lipoprotein-depleted plasma from a patient with abetalipoproteinemia has been assayed in a modified Glomset-Wright incubation system with three different normal lipoprotein substrates consisting of an authentic mixture of very low (VLDL), low (LDL) and high (HDL) density lipoproteins for the assay of total LCAT activity, HDL to assay alpha-LCAT activity and combined VLDL and LDL to assay beta-LCAT activity, respectively. Although reduced to about half the normal control values, both alpha- and beta-LCAT activities were present in the patient's plasma. It has been shown earlier that secretion of LCAT is linked to that of VLDL, but since patients with abetalipoproteinemia cannot form either chylomicrons or VLDL, our results suggest that a secretion of these triglyceride-rich lipoproteins do not seem to be a prerequisite for a basal secretion of beta-LCAT.
King Gustaf V Research Institute, Stockholm, Sweden.
L
L
Holmquist
L A
LA
Carlson
J K
JK
Lloyd
D000012:Abetalipoproteinemia / Q000201:enzymology*; D000293:Adolescent; D002788:Cholesterol Esters / Q000097:blood; D006801:Humans; D008055:Lipids / Q000097:blood; D008297:Male; D007862:Phosphatidylcholine-Sterol O-Acyltransferase / Q000097:blood*
D002788:Cholesterol Esters; D008055:Lipids; D007862:Phosphatidylcholine-Sterol O-Acyltransferase